How to Buy Uipath Stock
Uipath Inc
Uipath is a software infrastructure company located in New York, United States, which is part of the Technology sector, and is traded under the ticker PATH on the NYSE exchange.
Uipath stock last closed at $15.94, down 0.13% from the previous day, and has increased 22.9% in one year. It has overperformed other stocks in the Software - Infrastructure industry by 0.23 percentage points. Uipath stock is currently +69.94% from its 52-week low of $9.38, and -19.66% from its 52-week high of $19.84.
As of Dec 18, 2025, there are 534.75M shares of PATH outstanding. The market cap of PATH is $8.52B. In the last 24 hours, 15.02M PATH shares were traded.
How to Buy Uipath Stock
Not sure how to invest in Uipath stock? Here's how.
- Figure out where to buy Uipath stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you decide where to buy Uipath stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Pick your payment method and add your information.
- Evaluate Uipath stock: The Uipath ticker symbol is PATH. Is Uipath stock a good investment? Should you buy shares of PATH? How do PATH's underlying business fundamentals look? Do top analysts think Uipath is a good buy? Why has PATH's stock price moved recently? (Hint: Our stock market analysis tools can help you figure out if PATH is a good stock to buy).
- Place your PATH trade: Decide if you will purchase PATH shares at the current market price or use a limit order to buy PATH stock at a specific price.
- Monitor your PATH position: Create a watchlist to track your position in Uipath shares.
Step 1: Figure out where to buy Uipath stock
You need a brokerage account to access the NYSE market and buy PATH shares.
Our preferred brokerage: eToro
Based on our experience, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world financial markets: From Technology to Industrials, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the right brokerage, you need to fill out some personal information so you are able to invest in PATH today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create a new trading account.
- Send your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on the best app for stock investing, your next step is to transfer the money for your investment:
Check out the video below to see the process of transferring money into your new investment account.
Step 4: Evaluate Uipath stock
Once you have identified the best place to buy Uipath stock, it's absolutely critical to evaluate their stock before you buy, so you can wrap your head around the risk and upside.
Uipath shares at a glance
Uipath Due Diligence Score
WallStreetZen was designed to help part-time investors do better fundamental analysis.
You can see all of the due diligence checks on PATH's stock page.
Is PATH stock undervalued or overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge PATH's true value.
Using relative valuations methods:
- PATH could be overvalued based on its P/E ratio of 37.95x, relative to Software - Infrastructure industry P/E ratio of 32.96x
- PATH may be undervalued based on its P/B ratio of 4.43x, relative to Software - Infrastructure industry P/B ratio of 10.11x
- PATH may be overvalued based on its PEG ratio of 1.46x
You can do additional valuation analysis on PATH's stock here.
PATH Financial Health
Pros:
- PATH's operating cash flow of $334.94M allows it to safely service it's debt of $72.02M.
- There are more short-term assets than short-term liabilities on the PATH balance sheet.
- PATH profit margin has gone up from -6.5% to 14.8% in the past year.
- PATH earnings of $62.82M is not sufficient to cover its interest payments.
- There are more short-term assets than long-term liabilities on the PATH balance sheet.
Cons:
- PATH has a relatively high debt to equity ratio of 0.51.
Is it a good time to buy PATH stock, according to Wall Street analysts?
Out of 11 Wall Street analysts who research PATH, the consensus analyst rating on PATH is a Hold
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Most Recent PATH Analyst Upgrades/Downgrades
Kirk Materne, a top 16% analyst from Evercore ISI Group maintains PATH with a hold rating and raises their PATH price target from $15.00 to $17.00, on Dec 4, 2025.
Siti Panigrahi, a bottom 9% analyst from Mizuho maintains PATH with a hold rating and raises their PATH price target from $14.00 to $15.00, on Dec 4, 2025.
Kingsley Crane, a top 24% analyst from Canaccord Genuity maintains PATH with a strong buy rating and raises their PATH price target from $15.00 to $19.00, on Dec 4, 2025.
Michael Turrin, a bottom 7% analyst from Wells Fargo maintains PATH with a hold rating and raises their PATH price target from $12.00 to $14.00, on Dec 4, 2025.
Wells Fargo's Michael Turrin raised their price target on Uipath (NYSE: PATH) by 16.7% from $12 to $14 on 2025/12/04. The analyst maintained their Hold rating on the stock.
UiPath reported its Q3 2025 earnings.
Acknowledging that management's guidance suggests further growth stabilization, Turrin cautioned that the stock price remains balanced at current levels, at least until clearer signs of traction are visible around the company's RPA+AI vision.
Earnings Report
For Q3 2026, UiPath reported:
- EPS of $0.16, which beat the Zacks Consensus Estimate of $0.14 and Q3 2025's $0.11.
- Revenue of $411.11M, which beat the Zacks Consensus Estimate by 4.71% and Q3 2025's $354.65M.
For Q4 2026, management guided:
- Revenue of $462M to $467M.
CEO Daniel Dines commented: “I am pleased with our third quarter results, delivering ARR of $1.782 billion, up 11 percent year-over-year, a testament to the team’s focus, consistent execution, and the momentum we're seeing as customers scale agentic automation across the enterprise.
“Enterprises are accelerating their AI and automation strategies, and they’re looking for a unified platform rather than standalone tools.
"Our ability to bring deterministic automation, agentic automation, and orchestration together in one trusted, governed system is a true differentiator.
"It’s delivering meaningful outcomes for customers and positions us well as we close out the year.”
Jeff Hickey, a top 43% analyst from UBS upgrades PATH to a hold rating and raises their PATH price target from $10.00 to $17.00, on Oct 23, 2025.
You can dive deeper into what analysts are saying on the Uipath stock forecast page.
PATH Technicals
PATH Performance Metrics
Last year, PATH revenue was $1.55B. During the past four year, PATH's revenue has grown by 17.66% per year. This was faster than the Software - Infrastructure industry average of 17.48%.
Dive into PATH's earnings and revenue performance here.
What are PATH executives and large shareholders up to?
Over the last 12 months, executives and large shareholders at PATH have sold more shares than they have bought.
Daniel Dines, CEO and Chairman of PATH, was the latest PATH insider to sell. They sold $730,170.00 worth of PATH shares on Dec 18, 2025.
Dig into more about who owns PATH stock here.
Does PATH stock generate passive income?
No, Uipath doesn't provide an income stream by paying out dividends.
What do other investors have to say about PATH?
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Place your PATH trade
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a given dollar amount, place a limit order.
Hit the Open Trade button and your broker will place your order.
If you want more info about buying stocks on eToro, click the helpful video below:
Step 6: Monitor your PATH position
Now that you own some PATH stock, you'll want to stay up-to-date on your company.
Make a watchlist to get notified of the latest news about your PATH stock.
PATH Feed
How to Buy Stock in Uipath
To reiterate, here are the 6 steps to buy Uipath stock:
- Figure out where to buy Uipath stock
- Open a brokerage account
- Deposit funds into your brokerage account
- Evaluate Uipath stock
- Place your PATH trade
- Monitor your PATH position
If you need a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Uipath, get started below.
Other "How To" Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.